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An insertion/deletion (I/D) polymorphism of Alpha2B-Adrenoceptor (ADRA2B) gene located on chromosome 2 
has been studied extensively in related to cardiovascular diseases. The main aim of the present study was to 
examine the potential association of D allele frequency of I/D polymorphism of ADRA2B gene in Malaysian 
essential hypertensive subjects with or without type 2 diabetes mellitus (T2DM). This study includes 70 hyper-
tensive subjects without T2DM, 65 hypertensive subjects with T2DM and 75 healthy volunteers as control sub-
jects. Genotyping of I/D polymorphism was performed by conventional PCR method. There was significant 
difference found in age, body mass index, systolic/diastolic blood pressure and high density lipoprotein choles-
terol level between the case and control subjects. DD genotypic frequency of I/D polymorphism was significantly 
higher in hypertensive subjects (42.84% vs. 29.33%; P=0.029) and in hypertensive with T2DM subjects (46.15% vs. 
29.33%; P=0.046) than control group. D allele frequency was higher in hypertensive group (67.41%) than control 
subjects (52.67%). However, no significant difference was found between the three genotypes of I/D polymor-
phism of ADRA2B gene and the clinical characteristics of the subjects. The result obtained in this study show D 
allele of ADRA2B gene was associated with essential hypertension with or without T2DM in Malaysian subjects. 
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Introduction 
Essential hypertension (EHT) is a major public 
health burden worldwide and it is a growing concern 
in Malaysia [1]. According to the National Health and 
Morbidity Survey in Malaysia (1996), a prevalence of 
33% or an estimated of 2.6 million Malaysian adults 
aged ≥30 years had hypertension [2]. In order to iden-
tify the candidate genes in predisposition to EHT, 
several studies had been carried out extensively in 
various populations and indicate the important con-
tribution of genetic variants of many gene loci to EHT 
[3, 4]. In that way, recent studies suggested that, a 
common variant (12Glu9) of the human α2B-adrenergic 
gene (ADRA2B) encodes a receptor protein leading to 
the insertion/deletion (I/D) of three consecutive glu-
tamate residues at amino acid positions 301 to 303 has 
been associated with EHT [5, 6], acute coronary events 
[7].  In-vitro studies showed,  I/D polymorphism of 
ADRA2B gene to affect an impaired agonist-induced 
desensitization of the receptor [8]. D variant of I/D 
p o l y m o r p h i s m  o f  A D R A 2 B  g e n e  i n f l u e n c e  t h e  s y m -
pathetic nervous system activity and meant of to de-
velop EHT. It was also associated with impaired first 
phase insulin secretion and may predict the develop-
ment of T2DM in subjects with impaired glucose tol-
erance [9]. 
In a population-based, prospective study on 912 
middle-aged men, the DD genotype was associated 
with an increased incidence of acute myocardial in-
farction [10]. In addition, a cross-sectional clinical 
study in the Brazilian population suggested that 
12Glu9 deletion polymorphism of ADRA2B gene 
might result in reduced autonomic responsiveness by 
altering cardiac sympathetic and vagal function during 
sustained handgrip exercise in normotensive obese 
women [11]. Another study indicated D allele may be 
implicated in impaired glucose metabolism leading to 
earlier manifestation of diabetes in predisposed sub-
jects in Greek population [12].  Int. J. Biol. Sci. 2008, 4 
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In Chinese men [13], the I allele of the ADRA2B 
gene was strongly associated with higher blood pres-
sure while D allele was not associated in a cohort of 
middle-aged men from Eastern Finnish population 
[14], however subjects with D allele had an increased 
risk of developing T2DM in Finnish population [9]. In 
a controlled 10 years follow-up study in 126 
non-diabetic control subjects and 84 newly diagnosed, 
middle-aged T2DM patients from Eastern Finland, 
predicted a greater increase in body weight among 
non-diabetic subjects but not in type 2 diabetic subjects 
[15]. In addition, I/D polymorphism of ADRA2B gene 
was not associated with late complications in type 1 
diabetic patients [16] and EHT [7,17]. These controver-
sial results initiated us to determine the association of 
I/D polymorphism of ADRA2B gene in Malaysian 
essential hypertensive subjects with or without T2DM. 
Materials and Methods   
Ethics 
The study protocol was approved by the Ethical 
Committee of the Faculty of Medical and Health Sci-
ence (UPM/FPSK/PADS/T-TAD/T7-MJKEtikaPPer 
/F01); Universiti Putra Malaysia (UPM). Written in-
formed consent was obtained from all the respondents.   
Study Subjects 
A total of 70 hypertensive subjects without T2DM 
and 65 hypertensive subjects with T2DM were re-
cruited in this study. All the patients were consecu-
tively attended at  UPM Physician clinic and the 
medical wards; Hospital Kuala Lumpur from April 
2006–April 2007. The subjects were selected under the 
inclusion and exclusion criteria. Essential hypertensive 
subjects were defined as those with systolic blood 
pressure (SBP) of ≥140 mm Hg and/or diastolic blood 
pressure (DBP) of ≥90 mm Hg, or those currently re-
ceiving anti-hypertensive therapy. After the subjects 
have been seated and rested for 5 minutes, the blood 
pressure was measured using an automated blood 
pressure meter (Omron, Japan) on the right arm of the 
subjects. T2DM was defined under the criteria of 
American Diabetes Association as fasting plasma glu-
cose was > 7.0mmol/L and the levels were obtained 
from the medical records of the subjects. Seventy five 
unrelated healthy individuals were recruited ran-
domly with a negative history of hypertension and 
diabetes from UPM staff members and the volunteers. 
They were categorized with resting SBP <140 and DBP 
< 90mmHg on at least two separate occasions and 
none of them were receiving any medications at the 
time of participation. The subjects were divided as 
group 1 (EHT without T2DM), group 2 (EHT with 
T2DM) and the control subjects as group 3. The sub-
jects were also categorized under the three major eth-
nic groups as Malays, Chinese and Indians. Ques-
tionnaires in both Malay and English language were 
prepared to asses the socio-demographic factors, his-
tory and the duration of hypertension and T2DM. 
Sample Collection and Biochemical Analysis 
Four-five milliliters of peripheral blood samples 
were collected and transferred into an EDTA tube 
(Becton Dickinson, Franklin Lakes, NJ) by a qualified 
phlebotomist. Plasma was separated from the blood by 
centrifuge at 4000rpm and stored at -20ºC until further 
analysis. Individual weight and height were obtained 
to calculate body mass index (BMI) using the formula, 
weight (kg)/ [height (m2)]. To determine the levels of 
triglycerides (TG), high density lipoprotein cholesterol 
(HDL-C) and total cholesterol (TC), plasma samples 
was analyzed using Hitachi-912 Autoanalyser 
(Mannheim, Germany) with kits supplied by Roche 
Diagnostics (Mannheim, Germany). Low density 
lipoprotein cholesterol (LDL-C) was calculated using 
Friedewald formula [18].  
Genotyping Methods 
Genomic DNA was extracted from peripheral 
blood using Genomic DNA isolation kit (BioBasic.Inc, 
Toronto, Canada). The concentration and the purity of 
extracted DNA were quantified by spectrophotometry, 
using biophotometer UVette (Eppendorf, Hamburg, 
Germany). To determine the I/D polymorphism of 
ADRA2B gene, polymerase chain reaction (PCR) 
method [7] was used with forward primer: 
5’-AGG-GTG-TTT-GTG-GGG-CAT-CT-3’ and reverse 
primer: 5’-CAA-GCT-GAG-GCC-GGAGACACT-3’ 
(synthesized by Research Biolabs, Selangor, Malaysia). 
A total volume of 25μL reaction mixture contain 20 
pmol of each primer, 0.4 mmol/L of dNTP, 2 mmol/L 
of MgCl2, 1x Taq buffer, 1 unit of NEB Taq DNA po-
lymerase (New England Biolabs, Beverly, MA, USA) 
and the template DNA was used for amplification of 
I/D polymorphism of ADRA2B gene. The PCR cycling 
conditions were carried out on iCycler (BioRad Labo-
ratories, Hercules, California, USA). The initial dena-
turation was set up for 10 minutes at 95°C followed by 
35 cycles of denaturation for 1 minute at 94°C, an-
nealing for 2 minutes at 58°C, extension for 1 minute at 
72°C and the final extension was at 72°C for 2 minutes. 
The size of the PCR products was clearly resolved on 
3% Metaphor agarose gel (Cambrex, East Rutherford, 
NJ, USA) which has been performed in Origins elec-
trophoresis  (Elchrom Scientific AG, Cham, Switzer-
land) and then the gel was stained in ethidium bro-
mide. The DNA fragments were visualized under UV 
light using Alpha Imager (Alpha Innotech, San Lean-
dro, CA). Identical results were obtained when geno-Int. J. Biol. Sci. 2008, 4 
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typing was performed on two separate occasions for 
10% of the samples. 
Statistical Analysis 
All the statistical analysis was carried out by us-
ing SPSS (Chicago, IL, USA) software version 14.0 for 
Microsoft Windows®. Clinical characteristics of all the 
subjects were expressed as mean ± SD. Continuous 
variables were compared between the groups by using 
two-tailed student’s t  test. Allelic frequencies were 
calculated by gene-counting method and the genotypic 
and allelic distribution of I/D polymorphism of 
ADRA2B gene were analyzed using  chi-square test. 
The effect of I/D genotypes of ADRA2B was analyzed 
using general linear model ANOVA for clinical 
charateristics. A level of P <0.05 was considered statis-
tically significant. 
Results  
A total of 230 subjects were recruited and 210 
subjects were included in this study, since 20 subjects 
were excluded due to inconsistent results of genotypes 
and the extreme clinical characteristic values. This 
study consisted of 70 hypertensive subjects (group 1) 
(mean age 57.00±11.02 years), 65 hypertensive subjects 
with T2DM (group 2) (mean age 57.62±9.76 years) and 
75 unrelated healthy controls as group 3 (mean age 
45.37±10.72 years). Table 1 shows the baseline charac-
teristics of all the study subjects. The majority of the 
subjects involved in this study were males [130 
(61.90%)] as compared to females [80 (38.10%)]. None 
of the healthy subjects had a family history of hyper-
tension but among group 1; 55.71 % and 66.15 % of 
group 2 subjects had a family history of either hyper-
tension or diabetes. There were no significant differ-
ences observed in all of the variables analyzed between 
the groups except for age, BMI, SBP, DBP and 
HDL-Cholesterol (p<0.05).   
Table 1. Baseline charecterisitics of all the subjects 
Parameters  Group 1  Group 2  Group 3 
Gender (M/F)  51/19*  40/25  39/36 
Age (Years)  57.00±11.02*  57.62±9.76*  45.37±10.72
Smoking 26/44  26/39  20/55 
Duration of EHT (Years)  6.86±6.24  5.92±6.29  - 
Duration of T2DM  
(Years) 
- 6.71±6.71  - 
Family History 
(Yes/No) 
39/31 43/22 - 
BMI (kg/m2)  25.63±4.15*  26.71±3.60*  23.96±4.15 
SBP (mm Hg)  160.21±19.26* 160.26±19.01* 125.98±8.81
DBP (mm Hg)  97.77±10.77*  93.82±4.47*  77.83±7.09 
TC (mmol/L)  4.88±1.36  5.16±1.62  5.12±1.39 
HDL-C (mmol/L)  0.88±0.41*  0.78±0.31*  1.68±1.10 
LDL-C (mmol/L)  3.50±1.35  3.87±1.55  3.38±1.21 
TG (mmol/L)  2.04±1.20  2.01±1.02  1.12±0.40 
* P value < 0.05 vs. group 3 obtained through two-tailed student’s t 
test. 
 
Genotypes of I/D polymorphism of ADRA2B 
gene was determined by separating the PCR amplified 
DNA fragments on gel electrophoresis (figure 1). The 
identification of 112 bp fragments for the long allele (I) 
and 103bp for short allele (D) was carried out. The 
genotypic and allelic distribution of I/D polymor-
phism of ADRA2B gene among the groups are shown 
in the Table 2. The results from this study show a high 
prevalence of DD genotype in the total hypertensive 
subjects (44.51%) when compared to control subjects 
(29.33%). The frequency of the D allele in group 1 was 
67.14% and 67.69% in group 2 when compared to 
group 3 subjects (52.67%). Significant difference was 
observed in genotypic and allelic frequencies among 
the case and control subjects (p<0.05).  
 
 
 
Figure 1: PCR products in 3% Metaphor agarose gel electrophoresis. Lanes 1, 3, 5, 6, 9, 10, 12 show heterozygous ID genotypes, 
lanes 2, 7, 8, 11, 13 show homozygous DD genotypes and lane 4 shows homozygous II genotype. M represents a 100 bp DNA ladder 
(Fermentas). 
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Table 2: Genotypic and allelic distributions of I/D polymor-
phism of ADRA2B gene among the groups. 
Group 1   
(70) 
Group 2 
(65) 
Group 3 
(75) 
Genotypes 
 
n (%)  n (%)  n (%) 
II  6 (8.57)  7 (10.77)  18 (24.00) 
ID  34 (48.57)  28 (43.08)  35 (46.67) 
DD  30 (42.86)  30 (46.15)  22 (29.33) 
Significance 0.029*  0.046*  - 
 Alleles I   46 (32.86)  42 (32.31)  71 (47.33) 
 D  94 (67.14)  88 (67.69)  79 (52.67) 
Significance 0.012*  0.011*  - 
Odds Ratio 
95% CI 
0.545 
(0.388-0.837) 
0.531 
(0.326-0.595) 
- 
* P value < 0.05 vs. group 3, obtained through Chi-square test 
 
The genotypic and allelic distributions of  I/D 
polymorphism of ADRA2B gene among male and fe-
male subjects are shown in Table 3. There was no sig-
nificant difference in either hypertensive group or in 
the control group, but in hypertensive subjects with 
T2DM there was statistically significant differences 
observed between the gender for genotypes (P=0.032) 
and alleles (P=0.012) for  I/D polymorphism of 
ADRA2B gene. 
In addition, the data was stratified to analyze I/D 
polymorphism of ADRA2B gene with three ethnic 
groups of Malaysia. There was no significant differ-
ence observed between Malays, Chinese and Indians 
(data not shown). According to the three genotypes of 
I/D polymorphism of ADRA2B gene, the data was 
stratified for the clinical characteristics of the subjects 
and compared using univariate analysis (Table 4). We 
found no significant differences for the clinical char-
acteristics of the subjects with II, ID and DD genotypes 
of I/D polymorphism of ADRA2B gene.  
 
Table 3: Genotypic and allelic distributions of I/D polymorphism of ADRA2B gene among male and female subjects. 
Genotypes Alleles 
II ID  DD  I  D 
  Gender 
n (%)  n (%)  n (%) 
P 
value
n (%)  n (%) 
P value  OR 
95% CI 
Male (51)  3 
(5.88) 
27 
(52.94) 
21 
(41.18)
33 
(32.35) 
69 
(67.65) 
Group 1 
 
Female (19)  3 
(15.79) 
7 
(36.84) 
9 
(47.37)
 
 
0.294  13 
(34.21) 
25 
(65.79) 
 
0.842 
 
0.920 
(0.418-2.023)
Male (40)  2 
(5.00) 
15 
(37.50) 
23 
(57.5) 
19 
(23.75) 
61 
(76.25) 
Group 2 
 
Female (25)  5 
(20.00) 
13 
(52.00) 
7 
(28) 
 
 
0.032* 23 
(46.00) 
27 
(54) 
 
0.012* 
 
0.366 
(0.171-0.780
Male (39)  9 
(23.10) 
21 
(53.80) 
9 
(23.10)
39 
(50.00) 
39 
(50.00) 
Group 3 
 
Female (36)  9 
(25.00) 
14 
(38.90) 
13 
(36.10)
 
 
0.366  32 
(44.40) 
40 
(55.60) 
 
0.517 
 
1.250 
(0.657-2.377)
* P value < 0.05 vs. group 3 obtained through Chi-square analysis. 
 
Table 4: Clinical characteristics of the subjects stratified according to the genotypes of I/D polymorphism of ADRA2B gene.  
 
Groups 
 
BMI 
 
SBP 
 
DBP 
 
BGL 
 
HDL-C  
 
LDL-C 
 
TG 
 
TC 
Group 1 
II 26.28+5.52 163.67+21.79 97.17+5.00 5.07+0.66 0.89+0.37 .3.37+0.71 2.12+0.93 4.68+0.59 
ID 25.91+4.02 159.03+16.47 96.18+7.95 5.31+0.59 0.98+0.47 3.32+0.91 2.17+1.39 4.80+1.00 
DD 25.18+4.11 160.87+22.08 99.70+13.88 5.19+0.47 0.78+0.33 3.72+1.79 1.88+1.01 5.01+1.79 
p  value  0.724 0.841  0.428  0.487 0.163  0.486  0.624  0.789 
Group 2 
II 25.47+4.40 164.86+21.54 96.29+2.50 13.14+4.40 0.65+0.25 4.02+0.89 1.95+0.64 5.06+0.80 
ID 27.01+3.39 160.26+17.82 93.55+5.21 11.04+3.92 0.78+0.35 3.79+1.32 2.09+1.11 5.11+1.44 
DD 26.58+3.76 158.65+21.02 93.45+3.15 12.59+6.44 0.83+0.22 3.96+2.09 1.87+0.97 5.29+2.15 
p  value  0.575 0.764  0.305  0.382 0.428  0.886  0.747  0.911 
Group 3 
II 22.71+2.82 125.11+9.26 76.17+6.81 4.52+0.84 1.12+0.51 3.38+1.15 1.37+0.70 5.17+1.34 
ID 24.21+4.54 126.68+8.25 78.46+7.30 4.68+0.93 1.10+0.39 3.42+1.37 1.78+1.13 5.05+1.37 
DD 24.57+4.35 125.59+9.62 78.18+7.10 4.54+0.96 1.13+0.33 3.31+1.00 1.78+1.30 5.19+1.51 
p  value  0.329 0.807  0.524  0.780 0.969  0.949  0.383  0.923 
Data are presented as mean±SD, p value>0.05. 
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Discussion 
To the best of our knowledge, there was no pre-
vious study reported on I/D polymorphism of 
ADRA2B gene in Malaysian essential hypertensive 
subjects with or without T2DM. This study probably is 
first of a kind to determine the association of I/D 
p o l y m o r p h i s m  o f  A D R A 2 B  gene in essential hyper-
tension with or without T2DM in Malaysian subjects. 
I/D polymorphism of ADRA2B located on human 
chromosome 2 [19] involves the deletion of three glu-
tamic acids from a repeat element in the third intra-
cellular loop of the protein [20]. D variant of the 
ADRA2B gene mediates the regulation of blood pres-
sure, sympathetic tone, lipolysis and insulin secretion 
[21, 22]. Several studies reported that I/D polymor-
phism of ADRA2B gene has been associated with an 
increased risk of acute coronary events [7], obesity [20] 
and sympathetic nervous system activity [23]. 
Therefore, DD genotype of ADRA2B gene confers an 
increased risk for EHT.  
In this present study, we determined the associa-
tion of I/D polymorphism of ADRA2B gene in EHT 
with or without T2DM. We found, DD genotypes/D 
allele of ADRA2B gene were associated with EHT with 
or without T2DM as compared with healthy individu-
als (p<0.05) in Malaysian subjects. There was statisti-
cally significant differences found between group 1 vs. 
group 3 (P=0.029) and group 2 vs. group 3 (P=0.046) 
which are in accordance with Swedish population [5], 
Black [6] and Finnish population [10]. The result of this 
study suggested that there is a possible association of 
deletion allele of ADRA2B gene in EHT with or with-
out T2DM in Malaysian subjects.  
This study supports the previous hypothesis that 
DD genotype and D allele of ADRA2B gene contribute 
to the development of hypertension. Vasoconstriction 
in humans is probably mediated by the ADRA2B [24] 
and the observed decreased agonist-promoted desen-
sitization property of the deletion variant [8] may 
suggest that the DD genotype confers increased vaso-
constriction that leads to increased peripheral resis-
tance – a common finding in hypertension [25]. How-
ever, the findings of this study are in contrast to the 
results of Snapir et al. [7] and Baldwin et al. [17] 
(p>0.05). The discrepancies with previous studies 
might be due to the ethnicity differences, heterogene-
ous population or by sampling bias.  
Study Limitations   
The present study has to be interpreted within the 
context of its limitations. First, the present study pro-
vided only the evidences of the association between 
I/D polymorphism of ADRA2B gene and EHT with or 
without T2DM at the gene level and did not address 
the mechanism or the functionality of the D variant. 
Second, the control subjects are not age, sex matched 
and they are relatively young as compared to case 
subjects. Although our study comprised fewer sub-
jects, the result of this study shows DD genotypes/D 
allele of ADRA2B gene has a strong association with 
EHT with or without T2DM. However, with the find-
ings of this study, further association studies with 
well-designed larger sample size subjects involving 
I/D polymorphism of ADRA2B gene or other candi-
date gene polymorphisms in related to cardiovascular 
diseases is recommended.   
Conclusion 
DD genotypes/D allele of I/D polymorphism of 
ADRA2B gene is possibly an important genetic marker 
or risk factor for EHT with or without T2DM in Ma-
laysian subjects.   
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